There’s a fine line between “vintage” and “outdated” when it comes to houses, a new survey suggests. That’s according to a ...

ANOTHER year, another promise that the NHS is being radically reformed to slash waiting lists. Given that they are 40 per ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

“We should have known that was going to happen. The intelligence has to be better,” he said. After the war Chandler worked as a painter and wallpaper hanger and bought an upholstery business with his ...

While beneficial for weight loss and digestion, it should be consumed in moderation to avoid risks like obesity and type 2 diabetes. Raw honey offers better benefits, and its medicinal properties ...

Getty And the propensity towards obesity is happening on a molecular level, as Professor Ferdinand von Meyenn, a senior author on the study at the Federal Institute of Technology in Zurich ...

In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

According to 2017 to 2018 National Health and Nutrition Examination Survey results, 42.5% of U.S. adults 20 years old and over have obesity. Older data from the same survey states that adults with ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

The numbers showed that both average body mass index (BMI) and obesity rates across the population fell in 2023, having risen steadily since 2013 before leveling in 2022. While we don't yet have any ...

A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to lose nearly a fifth of their value ...